UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 24, 2018
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts | 001-14041 | 04-2882273 | ||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||
400 Wood Road Braintree, MA 02184 (Address of principal executive offices, including zip code) | ||||||||||||
(781) 848-7100 (Registrant’s telephone number, including area code) | ||||||||||||
Not Applicable (Registrant’s name or former address, if changed since last report) | ||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | ||||||||||||
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||||||||
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||||||||
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||||||||
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||||||||||||
Emerging growth company o | ||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o | ||||||||||||
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On January 24, 2018, the Board of Directors of Haemonetics Corporation (the “Company”) elected Ellen M. Zane to serve as a Class II Director for a term expiring at the 2019 Annual Meeting of Shareholders and appointed Ms. Zane to serve as a member of both the Compensation Committee and Governance and Compliance Committee of the Board of Directors. Ms. Zane led the turnaround of Tufts Medical Center and Floating Hospital for Children in Boston, Massachusetts, where she retired as President and Chief Executive Officer in 2011 and currently serves as Vice Chair of the Board of Trustees. In addition to her other public company board experience, Ms. Zane served as a director of the Company from 2012 to 2016.
As a non-employee director of the Company, Ms. Zane will receive compensation as described in the “Directors’ Compensation” section of the Company’s 2017 Proxy Statement. In connection with her election, Ms. Zane received a grant of 1,301 Restricted Stock Units which vest on the first anniversary of the grant date and represent a prorated annual equity award based on the number of days to be served from Ms. Zane’s election through the first anniversary of the 2017 Annual Meeting of Shareholders.
A copy of the Company’s press release announcing the election of Ms. Zane is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit Number | Description | |
99.1 | ||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION | |||
Date: January 25, 2018 | By: | /s/ Christopher Simon | |
Name: | Christopher Simon | ||
Title: | President and Chief Executive Officer | ||
Exhibit 99.1
News Release | |||
FOR RELEASE: | INVESTOR CONTACT: | ||
Date January 25, 2018 | Gerry Gould, VP-Investor Relations | ||
Time 8:00 am Eastern | (781) 356-9402 | ||
gerry.gould@haemonetics.com | |||
MEDIA CONTACT: | |||
Carla Burigatto, VP-Communications | |||
(781) 348-7263 | |||
carla.burigatto@haemonetics.com | |||
Ellen M. Zane Rejoins Haemonetics Board of Directors
Braintree, Mass., Jan. 25, 2018 - Haemonetics Corporation (NYSE: HAE) announced the election of Ellen M. Zane to its Board of Directors. Zane is a nationally renowned health care leader with more than 30 years of experience in hospitals and health care systems.
Zane led the turnaround of Tufts Medical Center and Floating Hospital for Children in Boston, where she retired as President and Chief Executive Officer in 2011 and currently serves as Vice Chair of the Board of Trustees. She returned the organization to financial stability and strengthened its academic relationships and community physician networks to deliver high-quality, cost-efficient and patient-centered care amid rapid change in the health care industry.
From 1994 to 2004, Zane was Network President of Partners HealthCare System, Inc., where she developed one of the largest physician networks in the country. Prior to this, she was Chief Executive Officer of Quincy Hospital.
Zane serves on the board of global medical technology leader Boston Scientific Corporation, as well as the boards of Brooks Automation and Fiduciary Trust Company. She is also a former director of PAREXEL International Corporation. Zane previously served on Haemonetics’ Board of Directors from 2012-2016.
"We are pleased to welcome Ellen back to our Board. Her broad expertise in health systems and physician enterprises will bring valuable insights across the company’s growth businesses, especially our Hospital business unit,” said Richard J. Meelia, Chairman of Haemonetics' Board of Directors. “The Board is committed to renewal in support of Haemonetics’ turnaround. Ellen is the
1
fourth director to join in the past 18 months and will add to the Board’s strong mix of operational and strategic experience as the company transforms to pursue accelerated growth.”
Zane earned a Bachelor of Arts degree from George Washington University and a Master of Arts degree from The Catholic University of America, and holds honorary doctorate degrees from Bentley University, Stonehill College and Curry College. She is on the faculty at Tufts University School of Medicine and The Harvard T. H. Chan School of Public Health.
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
2